GCL
ONCE

Glazer Capital LLC’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Glazer Capital LLC’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-30,000
Closed -$3.42M – 178
2019
Q1 		$3.42M Buy
+30,000
New +$2.2M 0.5% 48

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Glazer Capital LLC's ONCE Position: Q2 2019 in Review

Glazer Capital LLC sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 30,000 shares — an estimated $3.42M sold.

Glazer Capital LLC first reported a position in ONCE in Q1 2019 and held it in 1 quarter. The position peaked at $3.42M in Q1 2019. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • Glazer Capital LLC reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Glazer Capital LLC sold 30,000 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $3.42M.
  • Glazer Capital LLC first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Glazer Capital LLC's Spark Therapeutics, Inc. Common Stock position peaked at $3.42M in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Glazer Capital LLC's 13F filing for Q2 2019, filed 15 Aug 2019.